Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc.ELOX · Entity 7180 | 10% owner | April 30, 2018 | May 01, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eloxx Pharmaceuticals, Inc.
Report date April 30, 2018 · Filed May 01, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,351,770 |
Reported balance
After 2018-04-30 transaction · row 1
1 source rowRow 1 · 2018-04-30 · Purchase · Acquired 75,000 · Balance 3,351,770 F1: Reflects the purchase of shares in the follow-on offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on April 30, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the purchase of shares in the follow-on offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on April 30, 2018.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 30, 2018 Filed May 1, 2018 20:39 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | PurchaseCommon Stock | 75,000 | $9.75 | $731,250.00 |
DisclosureSEC source: 0001209191-18-027116 · doc4.xml · nonDerivative · entry 1 Shabtai Gilad · CIK 0001726027 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,351,770 F1 · kind: Reflects the purchase of shares in the follow-on offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on April 30, 2018. Read SEC document |
| April 04, 2018 Filed Apr 5, 2018 22:08 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | PurchaseCommon Stock | 2,600 | $9.58 | $24,908.00 |
DisclosureSEC source: 0001209191-18-024125 · doc4.xml · nonDerivative · entry 2 Shabtai Gilad · CIK 0001726027 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,276,770 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.50 to $9.69666, inclusive. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 22:08 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | PurchaseCommon Stock | 5,700 | $9.41 | $53,637.00 |
DisclosureSEC source: 0001209191-18-024125 · doc4.xml · nonDerivative · entry 1 Shabtai Gilad · CIK 0001726027 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,274,170 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.39 to $9.413, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| March 29, 2018 Filed Apr 2, 2018 21:43 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | PurchaseCommon Stock | 4,500 | $9.64 | $43,380.00 |
DisclosureSEC source: 0001209191-18-022544 · doc4.xml · nonDerivative · entry 1 Shabtai Gilad · CIK 0001726027 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,268,470 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.63 to $9.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.